 Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of 10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is eligible to receive additional payments related to milestones, royalties, and product transfers Napo EUs initial focus is on accelerated conditional approval for orphan disease: short bowel syndrome with intestinal failure SAN FRANCISCO, CA ACCESSWIRE August 19, 2021 Napo Pharmaceuticals, Inc. Napo, the wholly owned US subsidiary of Jaguar Health, Inc. NASDAQ:JAGX, today announced the signing of a license agreement with Napos Italian subsidiary, Napo EU S.p.A. 